AUGMENTIN ES-600 SUSPENSION Rx
Generic Name and Formulations:
Amoxicillin 600mg, clavulanic acid (as potassium) 42.9mg; per 5mL; strawberry cream flavor (may add FLAVORx); contains phenylalanine.
Dr. Reddy's Laboratories, Inc.
Indications for AUGMENTIN ES-600 SUSPENSION:
Susceptible recurrent or persistent acute otitis media (see full labeling).
Take with food. Base dose on amoxicillin component. Due to clavulanic acid component, ES-600 is not interchangable with other susp formulations. <3months: not recommended. ≥3months (<40kg): 90mg/kg per day in 2 divided doses every 12 hours for 10 days. ≥40kg: not recommended.
History of Augmentin-associated cholestatic jaundice/hepatic dysfunction. XR: Severe renal impairment (CrCl <30mL/min) or hemodialysis.
Cephalosporin, imipenem, or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Hepatic dysfunction. Mononucleosis. Elderly (consider monitoring renal function). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Probenecid potentiates amoxicillin. May potentiate oral anticoagulants (monitor). May antagonize oral contraceptives.
Broad-spectrum penicillin + β-lactamase inhibitor.
Diarrhea, nausea, abdominal pain, rash, urticaria, vomiting, vaginitis; anaphylaxis.
XR tabs—28, 40; Tabs 250mg—30; Tabs 500mg, 875mg—20; Susp 125mg/5mL, 250mg/5mL—75mL, 100mL, 150mL; Susp 200mg/5mL, 400mg/5mL—50mL, 75mL, 100mL; Chew tabs 125mg, 250mg—30; Chew tabs 200mg, 400mg—20; Susp ES-600 600mg/5mL—50mL, 75mL, 100mL, 125mL, 150mL, 200mL
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D